Name

Mayinglong

Legal name

马应龙药业集团股份有限公司

Website

https://mayinglong.cn

Company type

Public

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Wuchang

HQ country

China

HQ region

Asia

Offices7 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D

Revenue model

1. Pharmaceutical Products: Core revenue stream from proprietary TCM hemorrhoid treatments (creams, suppositories), eye medications, and other pharmaceutical formulations. The company manufactures over 300 types of nationally approved drug products and 20+ exclusive varieties.
2. Medical Services: Revenue from 7 direct-operated anorectal specialty hospitals (Beijing, Xi'an, Wuhan, Shenyang, Nanjing, Datong, Ningbo) with 1200+ beds, plus co-built anorectal centers at 30+ public hospitals. Hospitals generate revenue through consultation, treatment, and procedures.
3. Big Health Products: Functional cosmetics (eye creams, skincare under '瞳话' brand), infant care products (diaper rash cream, baby wipes), and health supplements leveraging the Eight Treasures Formula brand equity.
4. E-commerce/Online Sales: Direct-to-consumer online store sales of pharmaceuticals, health products, and cosmetics through the company's e-commerce platform.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels6 records

Core offering

Mayinglong manufactures and sells traditional Chinese medicine (TCM) hemorrhoid and anorectal preparations built on the proprietary Eight Treasures Formula (八宝古方), alongside ophthalmic preparations such as eye drops. The portfolio extends into functional health, personal care and cosmetic SKUs, and is supported by a chain of anorectal specialty hospitals that deliver clinical services to anorectal patients.

Product overview

Mayinglong is a 440-year-old traditional Chinese medicine company (stock: 600993.SH) that has evolved from a single hemorrhoid medication manufacturer into a comprehensive health solution provider. The company operates three interconnected business segments: (1) Pharmaceutical Products including flagship hemorrhoid treatments (麝香痔疮膏, 麝香痔疮栓), traditional eye ointment (八宝眼膏), and skin treatment ointment (龙珠软膏); (2) Functional Cosmetics and Big Health Products including eye care brands (马应龙八宝眼霜, 瞳话), infant care products (婴童护理), and anorectal health supplements; and (3) Medical Services including 7 self-operated anorectal hospitals, 30+ co-built specialty centers through the Anorectal Diagnosis and Treatment Research Institute, the Xiaoma Medical cloud platform, and pharmacy chains. The company leverages its proprietary Babao Formula (八宝古方) as the foundation for product extensions across pharmaceuticals, cosmetics, and health supplements.

Differentiator

Problem solved

Functional benefit

Brands

• 马应龙八宝 (Mayinglong Babao): Professional eye care brand launched in 2009, extending Mayinglong's Eight Treasure formula into functional cosmetics for eye care.
• 瞳话 (Tonghua)
• 小马医疗 (Xiaoma Medical)
• 龙珠软膏

Products and services

• Mayinglong Hemorrhoid Ointment (马应龙痔疮膏) — Eight Treasures Formula TCM preparation Flagship OTC traditional Chinese medicine ointment for the treatment of hemorrhoids and related anorectal conditions, built on the proprietary Eight Treasures Formula (八宝古方). Sold over the counter through retail pharmacies, hospital channels, and online pharmacies to Chinese consumers.
• Mayinglong Eye Drops (马应龙眼药) Branded ophthalmic preparation for relief of eye fatigue, dryness, and minor ophthalmic discomfort. Sold as an OTC consumer healthcare product through pharmacies and e-commerce channels to Chinese consumers.
• Anorectal Specialty Hospital Services (肛肠专科医院) Clinical diagnostic and treatment services for anorectal diseases delivered through Mayinglong's chain of dedicated anorectal specialty hospitals. Targets patients requiring specialist care beyond OTC self-treatment.
• Functional Health and Personal Care Products (功能性健康与个护产品) Branded functional health, personal care and cosmetic SKUs that extend Mayinglong's anorectal and TCM expertise into adjacent consumer categories, distributed through retail and online channels.

Quantifiable outcome

• 40%+ retail market share in hemorrhoid medications (consistently for many years)
• +3 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Ten partnerships are on record, tiered core, major and minor.

• 中华中医药学会肛肠分会 (China Association of TCM Anorectal Branch)coreStrategic or Co-development Partner · 25 August 2015Strategic partnership for China's first large-scale anorectal disease epidemiological survey (2012-2015). Jointly conducted national survey covering 31 provinces, 197 cities/counties, with nearly 70,000 valid samples. Survey results published and used for national health policy reference.
• 北京大学药学院 (Peking University School of Pharmacy)coreTechnology or IntegrationLong-term strategic R&D partnership. Company established joint postdoctoral workstation with Peking University. Collaborates on new drug development and pharmaceutical technology research.
• 中国药科大学 (China Pharmaceutical University)majorTechnology or IntegrationStrategic R&D partnership for pharmaceutical research and development. Collaborates on drug formulation research and technology innovation.
• 湖北中医药大学 (Hubei University of Chinese Medicine)majorTechnology or IntegrationEstablished joint graduate workstation. Collaborates on talent cultivation and TCM research.
• 华润湖北医药 (China Resources Hubei Pharmaceutical)minorChannel Partner/ Reseller/ DistributorBusiness cooperation and communication meetings held to explore collaboration opportunities in pharmaceutical distribution and logistics.
• 浙江隆泰医疗科技股份有限公司 (Zhejiang Longtai Medical Technology)minorStrategic or Co-development PartnerStrategic cooperation in health care product field. Jointly developed and promoted healthcare products.
• 福娃集团 (Fuwa Group)minorStrategic or Co-development PartnerStrategic partnership for intestinal health food research, development and promotion. Combines TCM expertise with food science.
• 叮当快药 (Dingdang Kuaiyao)minorChannel Partner/ Reseller/ DistributorStrategic partnership to expand retail channels for digestive health biscuits (蔬通消化饼干). Part of 'FSC pharmacy enterprise alliance'.
• 英国驻武汉总领事馆 (British Consulate General Wuhan)minorGTM or Marketing PartnerUK trade and investment officials visited Mayinglong to explore cooperation opportunities in healthcare, big health and other fields. Represents potential international expansion interest.
• 小马医疗 (XiaoMa Medical)coreStrategic or Co-development PartnerMayinglong's internet medical platform - 'Small Ma Medical' (小马医疗). Specialized vertical mobile medical platform for anorectal healthcare. First round financing of 60 million yuan completed in 2016. Connects 800+ hospitals and 20,000+ anorectal specialists.

Scale indicators12 records

Recent moves8 records

Expansion highlights6 records

Emerging players

• Ping An Healthcare and Technology (平安好医生): Major Chinese digital healthcare platform providing telemedicine and health management. Comparable to Xiaoma Medical in the broader digital health platform category, though at vastly larger scale and broader scope.

Direct peers

• LBX Pharmacy Chain (老百姓大药房): Top-tier Chinese retail pharmacy chain with national presence. Comparable peer for Mayinglong's pharmacy retail business and downstream drug distribution.
• Aier Eye Hospital Group (爱尔眼科): Largest specialty hospital chain in China, operating across ophthalmology. Closest comparable business model to Mayinglong's vertically integrated specialty-hospital-plus-product strategy.
• Yifeng Pharmacy Chain (益丰药房): Major Chinese retail pharmacy chain operator with national footprint. Comparable to Mayinglong's direct pharmacy chain (Wuhan Mayinglong Pharmacy Chain, ~100 stores) in retail drug distribution model.
• Dingdang Kuaiyao (叮当快药): Online-to-offline pharmaceutical retail and digital health platform in China, also a Mayinglong FSC alliance partner. Comparable in digital pharmacy and health platform strategy.
• Tongrentang (北京同仁堂): China's most iconic heritage TCM pharmaceutical company, with a similar OTC drug portfolio, retail pharmacy network, and time-honored brand positioning. Closest comparable in heritage-driven TCM pharma model.
• China Resources Sanjiu (华润三九): Major Chinese pharmaceutical company focused on OTC TCM and consumer health products under the '999' brand. Comparable in OTC TCM scale, pharmacy distribution, and health product extensions.
• Pien Tze Huang (片仔癀): Major Chinese TCM pharmaceutical company with heritage positioning and premium OTC products. Comparable as a time-honored specialty TCM pharma with national brand recognition.
• Yunnan Baiyao (云南白药): Leading Chinese TCM pharmaceutical company with strong OTC presence and successful diversification into consumer healthcare products. Comparable in TCM pharma + consumer health dual-track strategy.

Broad incumbents

• Guangzhou Baiyunshan Pharmaceutical (广州白云山): Large diversified Chinese pharmaceutical group with significant TCM, OTC, and consumer health operations under the Baiyunshan brand. Comparable as a broad incumbent in TCM pharma and consumer healthcare.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/mayinglong-pharmaceutical-group-stock-co-ltd-

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mayinglong